Zobrazeno 1 - 10
of 218
pro vyhledávání: '"ML Dahl"'
Autor:
ML Dahl
Publikováno v:
Pharmacopsychiatry. 49
Autor:
Raul Allan Kiivet, Ly Rootslane, Adrián LLerena, T. Eklundh, J. Sanchez Vega, ML Dahl, F. Sjoqvist
Publikováno v:
British journal of clinical pharmacology. 40(5)
1. Patterns of drug treatment and the use of polypharmacy in schizophrenic in-patients were compared and evaluated in the University Teaching Hospitals of Psychiatry in Badajoz, Spain, Huddinge, Sweden, and Tartu, Estonia. 2. The medical records of u
Autor:
Christina Alm, ML Dahl-Puustinen, E Thunberg, I. Christenson, J Ostman, I Wikstrom, Leif Bertilsson
Publikováno v:
British journal of clinical pharmacology. 30(3)
The pharmacokinetics of a single oral dose of 1.75 mg glibenclamide were studied in 15 healthy Caucasians including five poor metabolisers of debrisoquine and five poor metabolisers of S-mephenytoin. Plasma glibenclamide concentrations and the urinar
Autor:
Schwieler L, Markus Larsson, Skogh E, Me, Kegel, Orhan F, Abdelmoaty S, Finn A, Bhat M, Samuelsson M, Lundberg K, Ml, Dahl, Sellgren C, Schuppe-Koistinen I, Svensson C, Erhardt S, Engberg G
Publikováno v:
Europe PubMed Central
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::32fd8315f208a5fab28bf9bdd3d85281
http://europepmc.org/abstract/med/25455350
http://europepmc.org/abstract/med/25455350
Publikováno v:
Scopus-Elsevier
Europe PubMed Central
Europe PubMed Central
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::228d5f44d3a8ec8ec5543dca2d33d229
http://www.scopus.com/inward/record.url?eid=2-s2.0-0038469903&partnerID=MN8TOARS
http://www.scopus.com/inward/record.url?eid=2-s2.0-0038469903&partnerID=MN8TOARS
Autor:
Griskevicius L, Yasar U, Sandberg M, Hidestrand M, Eliasson E, Tybring G, Moustapha Hassan, Ml, Dahl
Publikováno v:
Europe PubMed Central
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::bbc17a9f8799899aa4f3f99e8ca8703c
http://europepmc.org/abstract/med/12684728
http://europepmc.org/abstract/med/12684728
Publikováno v:
Scopus-Elsevier
Europe PubMed Central
Europe PubMed Central
Losartan, an angiotensin II receptor antagonist, is oxidized by hepatic cytochromes P450 to an active carboxylic acid metabolite, E-3174. The aim of the present investigation was to study the contribution of CYP2C9 and CYP3A4 in losartan oxidation in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::9a1c6b953a0c2531d9223a77af9ebc3d
http://www.scopus.com/inward/record.url?eid=2-s2.0-0034951038&partnerID=MN8TOARS
http://www.scopus.com/inward/record.url?eid=2-s2.0-0034951038&partnerID=MN8TOARS
Autor:
Börjesson A; Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.; Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden., Ekebergh M; Faculty of Caring Science, Worklife and Social Welfare, University of Borås, Borås, Sweden., Dahl ML; Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden., Ekström L; Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden., Lehtihet M; Department of Medicine, Karolinska Institutet, Stockholm, Sweden., Vicente V; The ambulance medical service in Stockholm (AISAB), Academic EMS Stockholm and Department of Clinical Science and Education, Södersjukhuset Karolinska Institutet, Stockholm, Sweden.
Publikováno v:
International journal of qualitative studies on health and well-being [Int J Qual Stud Health Well-being] 2024 Dec; Vol. 19 (1), pp. 2292826. Date of Electronic Publication: 2023 Dec 12.
Autor:
Mugusi S; Department of Clinical Pharmacology, School of Biomedical Sciences, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania., Mnkugwe RH; Department of Clinical Pharmacology, School of Biomedical Sciences, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania., Sanga AA; Department of Internal Medicine, Muhimbili National Hospital, Dar es Salaam, Tanzania., Salahuddin A; Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden., Barclay V; Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden., Shayo G; Department of Internal Medicine, School of Clinical Medicine, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania., Dahl ML; Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden., Aklillu E; Department of Global Public Health, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.
Publikováno v:
British journal of clinical pharmacology [Br J Clin Pharmacol] 2024 Nov; Vol. 90 (11), pp. 2823-2836. Date of Electronic Publication: 2024 Jul 11.
Autor:
Soeria-Atmadja S; Department of Clinical Science, Intervention and Technology, Division of Paediatrics, Karolinska Institutet, Stockholm, Sweden.; Department of Paediatrics, Karolinska University Hospital, Stockholm, Sweden., Amuge P; Baylor College of Medicine, Children's Foundation-Uganda, Kampala, Uganda., Nanzigu S; Department of Clinical Pharmacology & Therapeutics, Makerere University, Kampala, Uganda., Bbuye D; Baylor College of Medicine, Children's Foundation-Uganda, Kampala, Uganda., Eriksen J; Unit of Infectious Diseases/Venhälsan, Södersjukhuset, Stockholm, Sweden.; Department of Public Health, Karolinska Institutet, Stockholm, Sweden., Rubin J; Department of Clinical Science, Intervention and Technology, Division of Paediatrics, Karolinska Institutet, Stockholm, Sweden.; Department of Paediatrics, Karolinska University Hospital, Stockholm, Sweden., Kekitiinwa A; Baylor College of Medicine, Children's Foundation-Uganda, Kampala, Uganda., Obua C; Faculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda., Dahl ML; Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Stockholm, Sweden.; Department of Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden., Pettersson Bergstrand M; Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Stockholm, Sweden.; Department of Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden., Pohanka A; Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Stockholm, Sweden.; Department of Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden., Gustafsson LL; Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Stockholm, Sweden., Navér L; Department of Clinical Science, Intervention and Technology, Division of Paediatrics, Karolinska Institutet, Stockholm, Sweden.; Department of Paediatrics, Karolinska University Hospital, Stockholm, Sweden.
Publikováno v:
British journal of clinical pharmacology [Br J Clin Pharmacol] 2024 Oct 08. Date of Electronic Publication: 2024 Oct 08.